Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 34

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 34
---
2025, we announced that the first
patient has been enrolled in NCT06478641, an expanded access clinical study intended to confirm the activity of tafenoquine in treating
patients with persistent babesiosis who have failed standard of care treatment and are at high risk of experiencing a relapse.

<div align='center'>13</div>

ATM Offering

On July 12, 2024, we entered into an At-the-Market
Issuance Sales Agreement (the “ATM Agreement”) with WallachBeth Capital LLC (“WallachBeth”) to sell shares of
Common Stock having an aggregate offering price of up to $1,253,603 from time to time, through an “at the market offering”
program (the “ATM Offering”). On July 22, 2024, we filed an amendment to the prospectus supplement with the SEC to increase
the amount of Common Stock that may be offered and sold in the ATM Offering to $1,774,640 in the aggregate, inclusive of the shares of
Common Stock previously sold in the ATM Offering. On July 24, 2024, we filed a second amendment to the prospectus supplement with the
SEC to further increase the amount of Common Stock that may be offered and sold in the ATM Offering to $1,890,705 in the aggregate, inclusive
of the shares of Common Stock previously sold in the ATM Offering. On July 26, 2024, we filed a third amendment to the prospectus supplement
with the SEC to further increase the amount of Common Stock that may be offered and sold in the ATM Offering to $2,190,416 in the aggregate,
inclusive of the shares of Common Stock previously sold in the ATM Offering. On August 2, 2024, we filed a fourth amendment to the prospectus
supplement with the SEC to further increase the amount of Common Stock that may be offered and sold in the ATM Offering to $2,295,192
in the aggregate, inclusive of the shares of Common Stock previously sold in the ATM Offering. The offer and sale of shares of Common
Stock from the ATM Offering were made pursuant to our effective “shelf” registration statement on Form S-3 and an accompanying
base prospectus contained therein (Registration Statement No. 333-280796) which became effective on July 18, 2024. From July 19, 2024
to August 2, 2024, the Company sold a total of 135,